Multilayered proteomics reveals that JAM ‐A promotes breast cancer progression via regulation of amino acid transporter LAT1
Cancer Science · 2024
DOI: 10.1111/cas.16259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Kazufumi Magara und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Large Neutral Amino Acid-Transporter 1, Breast Neoplasms, Cell Adhesion Molecules, Disease Progression. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Recent studies have shown that transmembrane‐type tight junction proteins are upregulated in various cancers compared with their levels in normal tissues and are involved in cancer progression, suggesting that they are potential therapeutic targets. Here, we demonstrated the expression profile and a novel role of junctional adhesion molecule‐A (JAM‐A) in breast cancer. Immunohistochemistry of surgical specimens showed that JAM‐A was highly expressed from carcinoma in situ lesions, as in other adenocarcinomas, with higher expression in invasive carcinomas. High expression of JAM‐A contributed to malignant aspects such as lymph node metastasis and lymphatic involvement positivity. In breast cancer cells, JAM‐A expression status affects malignant potentials including proliferation and migration. Multilayered proteomics revealed that JAM‐A interacts with the amino acid transporter LAT1 in breast cancer cells. JAM‐A regulates the expression of LAT1 and interacts with it on the whole cell membrane, leading to enhanced amino acid uptake to promote tumor growth. Double high expression of JAM‐A and LAT1 predicts poor prognosis in patients with breast cancer. Of note, an antibody against an extracellular domain of JAM‐A suppressed the proliferation of breast cancer cells. Our findings indicate the possibility of JAM‐A‐targeted therapy ideally combined with LAT1‐targeted therapy as a new therapeutic strategy against breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Division of Tumor Pathology, Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.
- Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.
ORCID-Profile: Kazufumi Magara, Akira Takasawa, Yuna Nakamori, Makoto Osanai
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Magara, K., Takasawa, A., Takasawa, K., Aoyama, T., Ota, M., Kyuno, D., Ono, Y., Murakami, T., Yamamoto, S., Nakamori, Y., Nakahashi, N., Kutomi, G., Takemasa, I., Hasegawa, T., & Osanai, M. (2024). Multilayered proteomics reveals that JAM ‐A promotes breast cancer progression via regulation of amino acid transporter LAT1. Cancer Science. https://doi.org/10.1111/cas.16259
Vancouver
Magara K, Takasawa A, Takasawa K, Aoyama T, Ota M, Kyuno D, et al. Multilayered proteomics reveals that JAM ‐A promotes breast cancer progression via regulation of amino acid transporter LAT1. Cancer Science. 2024. doi:10.1111/cas.16259
BibTeX
@article{Magara2024,
author = {Magara, Kazufumi and Takasawa, Akira and Takasawa, Kumi and Aoyama, Tomoyuki and Ota, Misaki and Kyuno, Daisuke and Ono, Yusuke and Murakami, Taro and Yamamoto, Soh and Nakamori, Yuna and Nakahashi, Naoya and Kutomi, Goro and Takemasa, Ichiro and Hasegawa, Tadashi and Osanai, Makoto},
title = {Multilayered proteomics reveals that JAM ‐A promotes breast cancer progression via regulation of amino acid transporter LAT1},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16259}
}
EUVIMED